MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-30-2026
Sangamo Therapeutics Operating Expenses 2011-2026 | SGMO
Annual Operating Expenses Sangamo Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 161 M | 162 M | 450 M | 313 M | 294 M | 248 M | 208 M | 162 M | 92.9 M | 91.9 M | 86.4 M | 72.4 M | 50.8 M | 43.9 M | 46.1 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 450 M | 43.9 M | 165 M |
Quarterly Operating Expenses Sangamo Therapeutics
| 2025-Q3 | 2025-Q2 | 2024-Q3 | 2024-Q2 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 36.1 M | 36.2 M | 38.8 M | 37.4 M | 116 M | 130 M | 140 M | - | 81.4 M | 75.1 M | 73.5 M | - | 77 M | 76.6 M | 72.6 M | 69.2 M | 61.5 M | 59.4 M | 57.6 M | 53.4 M | 51.2 M | 51.1 M | 52 M | 47.6 M | 39.8 M | 40.6 M | 33.6 M | 26.8 M | 24.8 M | 21 M | 20.2 M | 18.8 M | 22 M | 30.5 M | 20.6 M | 24.8 M | 21.3 M | 20.6 M | 19.7 M | 19.4 M | 20.1 M | 17.4 M | 15.7 M | 15 M | 11.9 M | 12.4 M | 11.5 M | 12.3 M | 10.7 M | 10.3 M | 10.5 M | 11.1 M | 11.4 M | 11.8 M | 11.8 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 140 M | 10.3 M | 39.5 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
216 M | $ 21.94 | 2.48 % | $ 1.03 B |  USA |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
20.7 M | $ 0.9 | 0.49 % | $ 6.62 M | China |
 |
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B |  France |
 |
ACADIA Pharmaceuticals
ACAD
|
708 M | $ 22.66 | 3.19 % | $ 3.76 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | USA |
 |
AIkido Pharma
AIKI
|
179 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
196 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
46.2 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
13.3 M | - | 5.93 % | $ 314 M |  Canada |
 |
Brainstorm Cell Therapeutics
BCLI
|
31.7 M | - | -2.5 % | $ 5.88 M | USA |
 |
Applied Therapeutics
APLT
|
74.5 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
80 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
23.4 K | - | 17.91 % | $ 11.1 M | USA |
 |
BioNTech SE
BNTX
|
512 M | $ 102.75 | -2.57 % | $ 27.2 B | Germany |
 |
Avenue Therapeutics
ATXI
|
4.49 M | - | -52.27 % | $ 4.45 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
85.5 M | $ 4.14 | 1.35 % | $ 443 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
137 M | $ 23.58 | 1.38 % | $ 3 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M |  Israel |
 |
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.44 | -0.35 % | $ 383 M | Britain |
 |
Aptose Biosciences
APTO
|
24.7 M | - | -45.71 % | $ 1.2 M | Canada |
 |
AstraZeneca PLC
AZN
|
17.6 B | - | - | $ 96.9 B | Britain |
 |
AVROBIO
AVRO
|
71.7 M | - | 1083.1 % | $ 745 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 2.92 | -0.45 % | $ 4.81 M | Israel |
 |
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | Germany |
 |
bluebird bio
BLUE
|
854 M | - | - | $ 546 M | USA |
 |
ContraFect Corporation
CFRX
|
64.6 M | - | -5.16 % | $ 5.39 M | USA |
 |
Cardiff Oncology
CRDF
|
49.6 M | $ 1.72 | - | $ 115 M | USA |
 |
BioXcel Therapeutics
BTAI
|
107 M | $ 1.1 | 3.77 % | $ 13.4 M | USA |
 |
Cabaletta Bio
CABA
|
172 M | $ 2.99 | 1.19 % | $ 300 M | USA |
 |
Cara Therapeutics
CARA
|
26.7 M | - | -3.03 % | $ 260 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
47.6 M | - | 3.16 % | $ 1.9 M | USA |
 |
CASI Pharmaceuticals
CASI
|
38.9 M | - | - | $ 35.4 M | USA |
 |
CymaBay Therapeutics
CBAY
|
133 M | - | - | $ 3.45 B | USA |